1992
DOI: 10.1016/0006-291x(92)91631-y
|View full text |Cite
|
Sign up to set email alerts
|

Malignant transformation of rat thyroid cells transfected with the human TSH receptor cDNA

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
3
0
3

Year Published

1994
1994
2013
2013

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 9 publications
(6 citation statements)
references
References 22 publications
0
3
0
3
Order By: Relevance
“…Tumorigenic clones derived from FRTL-5 cells following transfection with a vector carrying the wildtype human TSHR cDNA have been previously described (Derwahl et al, 1992); however in this report, the authors failed to detect any expression of the transfected cDNA in the transformed clones, therefore raising question about the role played by the wild-type human TSH receptor in the acquisition of the tumorigenic phenotype. It should be emphasized, that under the conditions used in our experiments, no TSH-independent clones could be selected following transfection with wild-type human TSHR cDNA.…”
Section: Discussionmentioning
confidence: 71%
“…Tumorigenic clones derived from FRTL-5 cells following transfection with a vector carrying the wildtype human TSHR cDNA have been previously described (Derwahl et al, 1992); however in this report, the authors failed to detect any expression of the transfected cDNA in the transformed clones, therefore raising question about the role played by the wild-type human TSH receptor in the acquisition of the tumorigenic phenotype. It should be emphasized, that under the conditions used in our experiments, no TSH-independent clones could be selected following transfection with wild-type human TSHR cDNA.…”
Section: Discussionmentioning
confidence: 71%
“…There have been several reports on the transformation of FRTL-5 cells with virus and/or active oncogenes (Fusco et al, 1981(Fusco et al, , 1985(Fusco et al, , 1987Ferrentino et al, 1984;Berlingieri et al, 1990), chemical agents (Tramontano et al, 1986a;Sugawa et al, 1989) human TSH receptor cDNA (Derwahl et al, 1992). We have gener- This result indicates that MDP may have a carcinogenic effect similar to ethyl methane sulphonate, a chemical mutagenic agent, which has been used to transform FRTL-5 cells (Tramontano et al, 1986a;Sugawa et al, 1989).…”
Section: Discussionmentioning
confidence: 92%
“…FRTL-5 has many characteristics of thyroid epithelial cells, such as thyroglobulin (Tg) synthesis, iodine concentration and thyroid-stimulating hormone (TSH)-dependent cell growth. However, after the establishment of mutated FRTL-5 cells by various methods, such as chemical mutagenesis (Tramontano et al, 1986a;Sugawa et al, 1989), transformation with virus, oncogenes or human TSH receptor cDNA (Fusco et al, 1981(Fusco et al, , 1987Ferrentino et al, 1984;Berlingieri et al, 1990;Derwahl et al, 1992) or cellular cloning (Endo et al, 1990), many of these cells have lost TSH-dependent growth and their differentiation markers. On the other hand, human thyroid cancers are often characterized by well-differentiated features that include Tg production and expression of Tg, thyroid peroxidase (TPO) and TSH receptor mRNA.…”
mentioning
confidence: 99%
“…(Eingegangen: I.Oktober 1996; in revidierter Form: 27. Juni 1997) N ach neueren Arbeiten zur Genese der SD-Autonomie stehen die TSH-Rezeptoren im Mittelpunkt der Diskussion (2,3,11,12,17). Die Heterogenität der TSH-Rezeptoren wird auf molekularbiologischer Ebene als Grund für unterschiedliche Wirkung auf Wachstum und Funktion angeführt.…”
Section: Nuklearmedizin 1998; 37: 12-16unclassified
“…Die Heterogenität der TSH-Rezeptoren wird auf molekularbiologischer Ebene als Grund für unterschiedliche Wirkung auf Wachstum und Funktion angeführt. Auch werden Mutationen der TSH-Rezeptoren für Effekte auf den Stoffwechsel verantwortlich gemacht (2,3,11,12,17). Es wird davon ausgegangen, daß unter endogener TSH-Suppression eine komplette Suppression des regelbaren SD-Gewebes besteht.…”
Section: Nuklearmedizin 1998; 37: 12-16unclassified